mass confirmation comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-05-24. Where a claim depends on a specific study, the study is described rather than over-claimed.
Published research on the intact protein is substantial, covering actin regulation, cell migration, and wound models. Research using the heptapeptide fragment specifically is far smaller, and much of the circulating material originates in supplier documentation rather than peer-reviewed reports. Where fragment studies do exist, they often employ different sequences, chain lengths, or terminal modifications, which complicates direct comparison across papers. Readers encountering claims about TB-500 should therefore separate evidence about thymosin beta-4 from evidence about the fragment itself.
Discussion of the compound frequently appears alongside other short peptides described as fragments of larger proteins. That grouping is convenient but can be misleading, because fragment length, charge, and modification state determine how a peptide behaves in solution and in any experimental system. A seven-residue acetylated peptide and a full-length protein differ in mass by roughly an order of magnitude, and they cannot be assumed to share distribution or binding properties. Precision about which molecule is under discussion is the single most useful step when reading such material.
TB-500 is a shorthand label used in supplier catalogs and online discussion for a short synthetic peptide described as a fragment of thymosin beta-4. Most product listings present it as the N-terminally acetylated heptapeptide Ac-LKKTETQ, a sequence corresponding to the actin-binding region of the parent protein. The name is not a formal chemical designation and does not appear in standard nomenclature systems. Because labeling practices vary between vendors, two products sold under the same name may not contain the same molecule, and the stated sequence should be treated as a claim rather than a fixed definition.
TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.
Thymosin beta-4 itself is a natural peptide of 43 residues found in many cell types and body fluids. Its best-characterised function is binding and sequestering actin monomers, which influences cytoskeletal dynamics. The sequence most often associated with TB-500, LKKTETQ, corresponds to part of that actin-binding region. A different fragment, Ac-SDKP, is also derived from the same parent peptide and is studied in its own right, which is one reason discussions of thymosin fragments can become confusing. The two are structurally distinct and are not interchangeable.
Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.
| Property | Value | Notes |
|---|---|---|
| Reported sequence | Ac-LKKTETQ | Described in most listings as the actin-binding region of thymosin beta-4 |
| Reported molecular weight | Approximately 889 Da | Value shifts with the stated sequence; compare against the certificate of analysis |
| Parent protein length | 43 amino acids | Thymosin beta-4; the fragment covers only a small part of it |
| Common synonyms | TB4 fragment; thymosin beta-4 fragment | Trade-style names rather than formal nomenclature |
| Formal monographs | Not established | Labeling conventions differ by supplier and region |
Peptide bonds are susceptible to hydrolysis under extreme pH and to enzymatic cleavage if proteases are present. Heat, oxidising agents, and prolonged exposure to light also contribute to loss of material. Aggregation can occur at high concentrations or in certain buffer systems, and it may not be visible to the eye. Storage at -20 C or below is typical for both powder and aliquoted solutions, and desiccation of the powder is preferred.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography together with mass spectrometry. The chromatogram provides a purity estimate as a percentage of total peak area, while the mass spectrum confirms that the observed mass matches the expected value. Amino acid analysis or tandem mass spectrometry sequencing can provide additional confirmation. Reported purity figures depend on the column, gradient, and detection wavelength, so values from different laboratories are not directly comparable without method details.
TB-500 is a synthetic seven-residue peptide whose sequence, LKKTETQ, matches the N-terminal actin-binding region of thymosin beta-4. It is usually supplied in an N-terminally acetylated form, a modification that blocks the free amino terminus and can influence behavior in solution. In the research literature the same sequence appears under several names, including thymosin beta-4 fragment and shortened thymosin beta-4. Because it is a short peptide rather than the full 43-residue parent protein, its measured properties differ from those reported for thymosin beta-4 as a whole, and the two are not interchangeable in experimental design.
Thymosin beta-4 itself is a small, widely expressed protein that sequesters monomeric actin and participates in cell migration, angiogenesis, and tissue repair. Researchers have examined the shortened fragment as a possible mimic of some of these activities, reasoning that the actin-binding motif lies within the first few residues. Binding to monomeric actin has been observed in cell-free systems. Whether the fragment reproduces the broader effects of the full protein in living tissue remains an open question, and findings from animal models are frequently cited without a clear bridge to human physiology.
Discussion of TB-500 appears in several distinct literatures that rarely cite one another. Peer-reviewed studies usually describe in vitro assays or small animal experiments and are cautious about extrapolation. Veterinary and sports communities circulate anecdotal reports with limited methodological detail. Commercial listings add a third layer, often using the name interchangeably with thymosin beta-4 even though the two molecules differ in size and sequence. Regulatory status varies by country, and the compound is not a licensed medicine in most jurisdictions, so readers comparing sources should check which molecule and which purity each source actually describes.
== External links == Genome-based Peptide Fingerprint Scanning (GFS) Documentation Archived 27 September 2013 at the Wayback Machine Facebook link to "Genome-based Peptide Fingerprint Scanning" Explanation of MS/MS in relation to MASCOT
After Count Henry's death in 1112, Teresa ruled Portugal as queen. Her close association from 1121 with Fernando Pérez de Traba, a Galician noble, displeased the local nobility, who sided with her son, Afonso Henriques, defeating her and her supporters at the Battle of São Mamede in 1128. The following year, Afonso claimed sole authority over the entire county, free from foreign influence. According to legend, he won the Battle of Ourique and took the title of King in 1139. Afonso's claim was implicitly recognised by Alfonso VII of León at the Conference of Zamora in 1143, and by Pope Alexander III in 1179 through the papal bull Manifestis Probatum. With the support of north-European crusaders and Christian military and religious orders, Afonso Henriques and his successors continued pushing south until the capture of Algarve, the southernmost region of mainland Portugal, which was recognised by the Kingdom of Castile as Portuguese territory in 1267. With minor readjustments, Portugal's borders have largely remained the same since the signing of the Treaty of Alcañices between Denis of Portugal and Fernando IV of Castile in 1297. Between the 14th and early 15th century, Portugal was struck by several outbreaks of the plague, civil wars, invasions, famines, and natural disasters that led to a population decrease, labour shortages, and rise in antisemitism.
=== Combination hemoglobinopathies === A combination hemoglobinopathy occurs when someone inherits two different abnormal hemoglobin genes. Alpha thalassemia can coexist with other hemoglobinopathies such as sickle cell disease and beta thalassemia. When alpha thalassemia carrier or trait combines with another hemoglobinopathy, the symptoms are generally those of the other condition.
Sources: en.wikipedia.org
==== Pit closures ==== Heseltine's responsibilities also included Energy, as the separate Energy ministry was abolished. Electricity companies now decided on their own contracts, rather than being obliged by the government to choose British coal. With plans being made for the privatisation of British Coal, on 13 October 1992 Heseltine and British Coal both separately announced that 31 of British Coal's 50 pits were to close, with the loss of 30,000 jobs. Most of the detailed work had been done by the minister of state Tim Eggar. Many of the mines in Nottinghamshire that had continued working during the 1984–1985 strike were to close. Although this policy was seen by the Nottinghamshire miners as a betrayal, there was hardly any organised resistance to the programme. The government stated that since the pits were losing money they could be sustained only through unjustifiable government subsidies. Mine supporters pointed to the mines' high productivity rates and to the fact that their monetary losses were due to the large subsidies that other European nations were giving to their coal industries. An early leak had seen little reaction but Heseltine was taken aback by the public anger. Over 100 pits had closed since the 1984–1985 strike. The closures were to be rushed because the Treasury, under pressure from Major, had agreed to make money for generous redundancy settlements available only in the 1992–1993 fiscal year.
== Further reading == Singerman, Ariel; Useche, Pilar (26 February 2019). "FE983/FE983: Impact of Citrus Greening on Citrus Operations in Florida". University of Florida Institute of Food and Agricultural Sciences Electronic Data Information Source. Retrieved 16 February 2021. Zheng, Desen; Armstrong, Cheryl M; Yao, Wei; Wu, Bo; Luo, Weiqi; Powell, Charles; Hunter, Wayne; Luo, Feng; Gabriel, Dean; Duan, Yongping (10 January 2024). "Towards the completion of Koch's postulates for the citrus huanglongbing bacterium, Candidatus Liberibacter asiaticus". Horticulture Research. 11 (3). Oxford University Press. doi:10.1093/hr/uhae011. PMC 11783299. Hunter, W.B., Sinisterra-Hunter, X. 2018. Emerging RNA Suppression Technologies to Protect Citrus Trees from Citrus Greening Disease Bacteria. Advances in Insect Physiology 55:163-199. https://doi.org/10.1016/bs.aiip.2018.08.001 Sandoval-Mojica, A.F.; Altman, S.; Hunter, W.B.; Pelz-Stelinski, K.S. 2020. Peptide conjugated morpholino's for management of the Huanglongbing pathosystem. Pest Manag. Sci. doi: 10.1002/ps.5877. https://doi:101002/ps.5877 Sandoval-Mojica, A.G.; Hunter, W.B.; Aishwarya, V.; Bonilla, S.; Pelz-Stelinski, K.S. Antibacterial FANA oligonucleotides as a novel approach for managing the Huanglongbing pathosystem. Sci. Rep. 11:2760. (2021). doi:10.1038/s41598-021-82425-8 Hunter, W.B.; Cooper, W.R.; Sandoval-Mojica, A.F.; McCollum, G.; Aishwarya, V.; Pelz-Stelinski, K.S. (2021).
Studies to date have been small and largely confined to single centers, and their authors have described them as preliminary or as proofs of principle. The observed changes are not specific to any one disease: no tumor-derived component is detected, and similar alterations occur in different diseases as well as with inflammation, physiological state or medication. Thermogram shape also depends on sample collection, anticoagulant, storage and scan rate, and reproducibility across laboratories has not been established. As of 2026, no diagnostic test based on plasma or serum thermograms has received regulatory approval.
=== Linear traps and 3D trap === 3D ion trap (or Paul trap) mass spectrometers are widely used but have limitations. With a continuous source, such as one utilizing electrospray ionization (ESI), ions generated while the 3D trap is processing other ions are not used, thereby limiting the duty cycle. Furthermore, the total number of ions that can be stored in a 3D ion trap is limited by space charge effects. Combining a linear trap with a 3D trap can help overcome these limitations. Recently, Hardman and Makarov have described the use of a linear quadrupole trap to store ions formed by ESI for injection into an orbitrap mass analyzer. Ions passed through an orifice and skimmer, a quadrupole ion guide for ion cooling and then entered the quadrupole storage trap. The quadrupole trap has two rod sets; short rods near the exit were biased so that most ions accumulated in this region. Because the orbitrap requires that ions be injected in very short pulses, kilovolt ion extraction potentials were applied to the exit aperture. Flight times of ions to the orbitrap were mass dependent, but for a given mass, ions were injected in bunches less than 100 nanoseconds wide (fwhm).
Sources: en.wikipedia.org
=== Online === Peters, known to his online followers as "Clav", became popular online by 2025 for his content focused on looksmaxxing on both Kick and TikTok. His alias "Clavicular" is based on the emphasis placed on clavicle width within the looksmaxxing community. He instructs fans on how to "ascend", or to become more attractive and ostensibly gain social power and sexual prospects as a result, and to "hardmaxx", a looksmaxxing term for undergoing intense and painful physical alterations. Peters' looksmaxxing content includes traditional bodybuilding and fitness training, along with "a new focus on sort of facial esthetics". He has participated in and advocated for looksmaxxing practices such as "bonesmashing", a pseudoscientific practice involving hitting one's facial bones with a hammer or fist in order to create microscopic bone fractures with the hope that one's jaw would heal in a more pleasing shape. Peters has also acknowledged taking methamphetamine to suppress his appetite and remain thin. He has spoken about taking anabolic steroids over several years to become more muscular, which, according to him, made him infertile by 2025 due to his body no longer naturally producing testosterone. By late 2025, he also began selling access to a self-improvement and looksmaxxing course called the "Clavicular System", later called "Clavicular's Clan", for $50 per month. The course provides guides on how to "ascend" and on suggested peptides to inject in order to do so.
These actions are largely responsible for the strongly reinforcing effects of nicotine, which often occur in the absence of euphoria; however, mild euphoria from nicotine use can occur in some individuals.
Platelet-rich plasma is increasingly used to enhance healing in dental and oral surgery, particularly for aging patients. PRP is derived from the patient's blood through centrifugation, concentrating growth factors that are crucial for wound healing and tissue repair.
Sources: en.wikipedia.org
Most listings describe it as a short acetylated peptide with the sequence Ac-LKKTETQ, presented as a region of thymosin beta-4. The label is a trade-style name rather than a standardized chemical name, so the exact content of a given vial depends on the supplier.
No. Thymosin beta-4 is a protein of 43 amino acids, while TB-500 is described as a short fragment of it. The two differ in size, structure, and the range of interactions each can support.
Naming for research peptides is not centrally coordinated, so vendors set their own labels and specifications. Differences in stated sequence, molecular weight, or purity documentation usually trace back to those independent labeling choices.
No. Thymosin beta-4 is a 43-residue natural peptide, while TB-500 is a commercial label applied to a short synthetic fragment of it. The two differ in length, sequence coverage and how they are handled in the laboratory.